Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. - Wikidata - wikimedia - TriplyDB

Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.

Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.

http://www.wikidata.org/entity/Q33211344

about

Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes A thirteen-gene expression signature predicts survival of patients with pancreatic cancer and identifies new genes of interest.Pathways to tamoxifen resistance.A model of estrogen-related gene expression reveals non-linear effects in transcriptional response to tamoxifen.Interrogating differences in expression of targeted gene sets to predict breast cancer outcome.Challenges of microarray data and the evaluation of gene expression profile signatures.Molecular profiling of platinum resistant ovarian cancer.A systems approach to clinical oncology: focus on breast cancer.Converting a breast cancer microarray signature into a high-throughput diagnostic test.Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer Pathway analysis of gene signatures predicting metastasis of node-negative primary breast cancer.Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression.Identification of functional networks of estrogen- and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer.Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer.Analysis of DNA microarray expression data Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept.Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence.Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures.COL1A1, PRPF40A, and UCP2 correlate with hypoxia markers in non-small cell lung cancer.Widespread alternative exon usage in clinically distinct subtypes of Invasive Ductal Carcinoma An integrated bioinformatics approach identifies elevated cyclin E2 expression and E2F activity as distinct features of tamoxifen resistant breast tumors.Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response.Expectations, validity, and reality in gene expression profiling.A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy.Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.The methyltransferase EZH2 is not required for mammary cancer development, although high EZH2 and low H3K27me3 correlate with poor prognosis of ER-positive breast cancers "Resurrection of clinical efficacy" after resistance to endocrine therapy in metastatic breast cancer.Gene expression profiles accurately predict outcome following liver resection in patients with metastatic colorectal cancer.A serum protein profile predictive of the resistance to neoadjuvant chemotherapy in advanced breast cancers.Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients

P2860

Q24605762-4B0A78E1-E93A-41F0-B7F9-134561A362EA Q24652481-6EC24F85-AD27-41EE-BAA8-2766810849DF Q28308069-77DEDDF9-4CCF-405D-B1BF-A7746326C3AC Q28540790-ECD5D163-61AB-4D53-8372-97991D54A5F4 Q28543021-6A44C4E2-DB88-42CF-B21F-82B726039FE1 Q30410836-B6C8E649-D782-4C38-983D-6F0F18207FBE Q30441001-FEF00AAA-F565-4733-8EC4-51DB6D7DE3F4 Q30535835-197A68A6-8C0F-4A5B-B16D-ED2C8FDBB9AE Q31122465-70B592CF-6B8C-473B-8FAE-10A922C873F0 Q31153861-B9964943-4116-45A3-98EB-C7DADD3B155C Q33227163-CD626A8E-3F81-47AD-AA9D-DD7DC0913D0C Q33238889-E0CFECD4-72EB-4F32-9D9C-D7A1DC0672EE Q33262104-16F049A0-A146-4F85-A97D-B00830B45591 Q33281087-CB3DA2EE-6E5C-4D87-A5A8-297F25743121 Q33300287-D5B397E6-BD17-41BA-9D41-A8760E784B7B Q33337206-17EEB908-4917-4529-9651-C45EC3AE5DC1 Q33338626-24D57ECF-66D4-4D41-992E-C85FA1118DD4 Q33361574-7A93AE75-CF6B-43C2-87CA-B5B743D62F3D Q33423808-80EC7C81-974A-4FF4-9F7F-7593201DDF71 Q33495831-E78AE586-8866-483F-BA97-4C37CBB9B49C Q33515843-3725FAB4-9B49-4B5E-B880-3BA488B3D66B Q33517932-DCA6C0E7-F38E-4A30-8910-3B4DC717A895 Q33530942-FACC4765-5295-4015-AF30-52BB46FC3B36 Q33571040-37D4EFDB-BB99-406C-8641-03EB8FD962F7 Q33788520-DD9AF8C0-E3BC-4FB6-B88C-E490F105350B Q33840757-7E600054-723D-4D3E-9EEE-00A6396BA81C Q33911898-4572A3D0-8A35-4B51-9A53-8875240F965B Q33971409-AD6CB57F-E540-4536-B74D-F7A02E55E71A Q33974305-6F02A414-C8F7-455F-B1D7-1BA1564B3E3D Q34020695-A294F0B2-491C-4DA8-A7F6-569436A9CC4C Q34029272-67730A7A-BEDE-4E68-A445-0CF10D818125 Q34356351-6F0D19A7-40E5-43D7-8B6D-79B9164C4A43 Q34549892-89DA19C9-5B00-4E70-BB04-69ECD7BBDE3E Q34857146-2D275CA8-D209-4536-AA41-DE5246CEBF25 Q34861658-0A653D07-4E38-4C2D-B6D1-3547EC7DEAC8 Q34973200-8212A1F5-CB2D-4AFA-8C5F-9FFC334C4DC6 Q35067591-A900B014-9ECB-4DF3-9263-701437730553 Q35497722-253E18DC-F706-43D5-AF31-3D1B75C6F65A Q35558070-D48AF9E1-1A87-42F3-8A91-365E5E5EBFE9 Q35595696-7A08B274-10BE-4F05-8D19-FA5E42B472E4

P2860

Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.

http://www.wikidata.org/entity/Q33211344

description

2005 nî lūn-bûn

@nan

2005 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Molecular classification of ta ...... by gene expression profiling.

@ast

Molecular classification of ta ...... by gene expression profiling.

@en

type

label

Molecular classification of ta ...... by gene expression profiling.

@ast

Molecular classification of ta ...... by gene expression profiling.

@en

prefLabel

Molecular classification of ta ...... by gene expression profiling.

@ast

Molecular classification of ta ...... by gene expression profiling.

@en

P1433

Q33211344-6CC89D1D-CF27-4790-AACE-46160A2F7EE0

P1476

Q33211344-09711F89-9580-424F-A90B-CC91DBFC764B

P2093

Q33211344-30079855-359F-458D-AAB7-515493BA58ED

Q33211344-316E1796-7561-4979-8B59-B2A5760B359A

Q33211344-4018FF53-7C7E-452D-946B-D989AF4F7D1D

Q33211344-700FDD86-4119-4359-8250-36C8E0111EAE

Q33211344-8A3E6E90-08CB-434A-9BDC-EC0088A6F045

Q33211344-91E3D024-FFB4-4A2F-B21C-74F6B03473C5

Q33211344-98EC4352-85A9-4E8D-9A61-CE7FA1A72712

Q33211344-B36D2835-D5BC-4E1D-9030-0F54B3470A10

Q33211344-CB37974F-3261-430B-8699-2C242D12EE1F

Q33211344-E6E89AB2-DCEC-445F-8452-D2C1699F81AB

P304

Q33211344-5A98B1D0-E651-4905-A245-3570236FEDA6

P31

Q33211344-428EBA7E-3E80-4839-A282-E28A9E748DBE

P356

Q33211344-F1D00CBB-4DC2-44B2-AC26-840CE06CEDAB

P407

Q33211344-852F6FEE-EB4B-4CC3-A834-766B949E900D

P433

Q33211344-011694ED-DAC5-46E7-8C98-E0441068646F

P478

Q33211344-84D06E74-1B3C-4A36-AB2E-5E7DAE203B17

P577

Q33211344-E029AA24-39D2-4C53-8E74-BED2579671BA

P5875

Q33211344-51B36C00-D2F5-41F1-A757-03B00A98AF6C

P698

Q33211344-B0769ACC-EDB0-4547-8C8A-7D667F7844D5

P356

JCO.2005.05.145

P1433

Journal of Clinical Oncology

P1476

Molecular classification of ta ...... by gene expression profiling.

@en

P2093

Anieta M Sieuwerts

http://www.w3.org/2001/XMLSchema#string

Els M J J Berns

http://www.w3.org/2001/XMLSchema#string

Henk Portengen

http://www.w3.org/2001/XMLSchema#string

Iris L van Staveren

http://www.w3.org/2001/XMLSchema#string

Jan G M Klijn

http://www.w3.org/2001/XMLSchema#string

John A Foekens

http://www.w3.org/2001/XMLSchema#string

Kirsten Ritstier

http://www.w3.org/2001/XMLSchema#string

Lambert C J Dorssers

http://www.w3.org/2001/XMLSchema#string

Maaike M Dirkzwager-Kiel

http://www.w3.org/2001/XMLSchema#string

Marion E Meijer-van Gelder

http://www.w3.org/2001/XMLSchema#string

P304

732-740

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.05.145

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8049820

http://www.w3.org/2001/XMLSchema#string

P698

15681518

http://www.w3.org/2001/XMLSchema#string